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At least 12 genes (FH, HIF2A, MAX, NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, and VHL) have been implicated
in inherited predisposition to phaeochromocytoma (PCC), paraganglioma (PGL), or head and neck paraganglioma (HNPGL) and a
germlinemutationmay be detected inmore than 30%of cases. Knowledge of somaticmutations contributing to PCC/PGL/HNPGL
pathogenesis has received less attention though mutations in HRAS, HIF2A, NF1, RET, and VHL have been reported. To further
elucidate the role of somatic mutation in PCC/PGL/HNPGL tumourigenesis, we employed a next generation sequencing strategy
to analyse “mutation hotspots” in 50 human cancer genes. Mutations were identified for HRAS (c.37G>C; p.G13R and c.182A>G;
p.Q61R) in 7.1% (6/85); for BRAF (c.1799T>A; p.V600E) in 1.2% (1/85) of tumours; and for TP53 (c.1010G>A; p.R337H) in 2.35%
(2/85) of cases. Twenty-one tumours harboured mutations in inherited PCC/PGL/HNPGL genes and no HRAS, BRAF, or TP53
mutations occurred in this group. Combining our data with previous reports ofHRASmutations in PCC/PGLwe find that themean
frequency ofHRAS/BRAFmutations in sporadic PCC/PGL is 8.9% (24/269) and in PCC/PGL with an inherited gene mutation 0%
(0/148) suggesting that HRAS/BRAF mutations and inherited PCC/PGL genes mutations might be mutually exclusive. We report
the first evidence for BRAF mutations in the pathogenesis of PCC/PGL/HNPGL.
1. Introduction
Phaeochromocytoma (PCC) and paraganglioma (PGL) are
neuroendocrine tumours deriving from chromaffin cells of
the medulla of the adrenal glands or from extra-adrenal
chromaffin tissue like ganglia of the sympathetic nervous
system, respectively. Approximately 10% of tumours are
malignant but the most common presentation results from
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the cardiovascular effects of catecholamine hypersecretion
that causes hypertension, tachycardia, excessive sweating,
and/or anxiety. The majority of PCC/PGL occur sporadically
but although only about 10% of cases have a family history,
more than a third of cases harbour a germline mutation in
one of the 12 inherited PCC/PGL genes (FH, HIF2A, MAX,
NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127,
and VHL) that have been shown to be mutated in multiple
families and some of these genes are also somatically mutated
in sporadic PCC/PGL [1–8]. Germline mutations in most of
these genes may also cause head and neck paraganglioma
(HNPGL) which are derived from parasympathetic nervous
system ganglia and are nonsecretory [9–12]. It appears that
disruption of multiple cellular signalling pathways is impli-
cated in PCC/PGL/HNPGL tumourigenesis. Thus known
inherited predisposition gene products belong to multiple
functional classes including kinase receptor and signalling
regulators (RET and NF1), transcription factors (MAX),
energy metabolism components (FH, SDH-subunits A, B,
C, and D, and cofactor SDHAF2), constituents of the cel-
lular response to hypoxia (VHL and HIF2A/EPAS1), and
endosomal signalling (TMEM127) [1–8, 13–15]. Nevertheless,
gene expression studies have suggested that most PCCs and
PGLs can be classified into two distinct groups (cluster 1
and cluster 2) by transcription profiling: cluster 1 includes
tumours that harbour mutations in genes linked to the
hypoxic gene response (VHL, HIF2A, SDHA, SDHB, SDHC,
and SDHD) and cluster 2 contains tumours harbouring
mutations in genes that are involved in the kinase signalling
characterized by the activation of the PIK3/AKT/mTOR and
RAS/RAF/ERK pathways (RET, NF1, TMEM127, MAX, and
HRAS) [14–18].
The last 10 years have seen considerable progress in
identifying the genetic basis of inherited PCC/PGL/HNPGL,
but relatively less progress has been made with respect to
understanding the somatic mutations that underlie tumour
initiation and progression in these tumour types. Somatic
mutations in inherited PCC/PGL genes can be detected in
∼25–30% of the sporadic tumours (mainly involving RET,
VHL, NF1, MAX, and HIF2A genes). Recently, an exome
resequencing study led to the identification of somaticHRAS
activating mutations in sporadic PCC/PGLs [19]. Subse-
quently, this finding was confirmed and the overall frequency
of somatic HRAS mutations has been estimated at about 7%
[20]. However, to dateHRAS analysis in PCC/PGLhasmostly
been performed by Sanger sequencing and the frequency of
HRASmutationsmight have been underestimated because of
the lower sensitivity of Sanger sequencing analysis, compared
to next generation sequencing approaches, to detect mosaic
mutations [21]. Furthermore, in contrast to many other
tumour types, there is little information available on many
of the genes most commonly mutated in human neoplasia.
We therefore investigated, in tumour samples, the frequency
of mutations in critical regions of 50 human cancer genes
by next generation sequencing in a large series (𝑛 = 85) of
inherited and sporadic PCC/PGL/HNPGL.
2. Materials and Methods
2.1. Subjects. Tumour material from 85 patients with PCC
(𝑛 = 60), PGL (𝑛 = 5), or HNPGL (𝑛 = 20) was collected
for analysis. 21 patients were known to harbour a germline
inherited gene mutation (VHL = 10, RET = 3, NF1 = 1, SDHB
= 5, SDHC = 1, and SDHD = 1) and 64 cases were sporadic. All
patients gave informed consent and the study was approved
by the South Birmingham Ethics Committee.
2.2. Next Generation Sequencing (NGS)
2.2.1. Technical Assessment. To investigate the sensitivity of
somatic mutation detection, a dilution series of two well
characterized DNA samples was created. A sample bear-
ing HRAS (c.81T>C) and one a PIK3CA (c.1173A>G) were
titrated together to create serial dilutions containing allelic
frequencies ranging from 50% to 0.1%. Each dilution was
amplified using the Ion AmpliSeq Cancer Hotspot Panel
v2 (Life Technologies, UK). Amplicons underwent library
preparation according to protocol. Before emulsion PCR
each point of the titration curve was identified by using a
different Ion Xpress Barcode. Subsequently library was run
on 318 chip v2 (Life Technologies, UK) on the Ion PGM
(Life Technologies, UK). The output reads from the chip
were processed using the Torrent browser suite software
(v.4.0.2).
2.2.2. Sample Sequencing. DNA was isolated from both
tumour material and peripheral blood using standard
methodology. Genomic DNA (gDNA) samples were quality-
checked on DNA NanoDrop 1000 considering acceptable
absorbance ratio greater than 1.7 for both 260/280 and
230/260 nm. Each sample was then quantified with the
Qubit2.0 fluorometer (Life Technologies, UK) by using the
Quant-IT dsDNA BR Assay (Life Technologies, UK). For
the AmpliSeq Library, 10 ng of gDNA was used for library
generation. Libraries were indexed using the Ion Xpress
Barcode Adapter Kit and quantified using the Quant-IT
dsDNA HS Assay (Life Technologies, UK) on Qubit 2.0.
Appropriate dilutions were performed based on amplicon
concentration at the 80–125 bp range. Twenty pM of indi-
vidual indexed amplicon libraries were pooled for emulsion
PCR and 16 samples were sequenced on the Ion Torrent PGM
platform using the 318 v2 chip (Life Technologies, UK). Mean
coverage for each sample was over 1000x. Sequence reads
were mapped against the human reference genome (hg19)
with the Torrent Mapping Alignment Program (TMAP)
using the default software settings. Output was restricted
to the targeted regions as defined by the sequence capture
design BED file, and SNPs and INDELs were characterized
as being significantly different from the reference sequence
if the variant to reference base frequency was greater than
5%. All identified variants within a particular sample were
saved as variant call format file (VCF version 4.1). VCFs were
examined with the online tool “Ingenuity Variant Analysis”
(Qiagen) for variant annotation and prediction of variant
effects on genes. In addition, BAM files were inspected
manually in order to remove likely artefactual variants (i.e.,
close to homopolymers) and to detect any mutations in
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Table 1: Mutations detected in inherited PCC/PGL/HNPGL genes.
Tumour ID Type of tumour Gene Mutation type
P1 PCC RET c.1900T>C
P2 PCC RET c.1901G>A
P3 PCC RET c.2753T>C
P4 PCC VHL c.241C>T
P5 PCC VHL c.292T>C
P6 PCC VHL c.292T>C
P7 PCC VHL c.292T>C
P8 PCC VHL c.292T>C
P9 PCC VHL c.292T>C
P10 PCC VHL c.292T>C
P11 PCC VHL c.292T>C
P12 PCC VHL c.292T>C
P13 PCC VHL c.374A>C
P14 PCC SDHB c.470delT
known driver genes, especially insertions and deletions that
were not called by the Ion Torrent software.
2.3. Sanger Sequencing. To confirm NGS results, fragments
of hotspot codons in HRAS (exons 2 and 3), BRAF (exon
15), and TP53 (exon 10) were amplified, in both tumour and
constitutional (blood) DNA, by PCR and sequenced with
automated Sanger sequencing. Primers sequences and PCR
conditions are available on request.
2.4. Statistical Analysis. Patients with mutated HRAS and
BRAF were compared to patients with negative genetic
screening.
𝑃 values <0.05 were considered statistically significant.
3. Results
3.1. Technical Assessment of Next Generation Sequencing
Assay. The analytical sensitivity of the AmpliSeq Hotspot
panel was determined using serial dilutions of tumour DNA
carrying PIK3CA and HRAS mutations. This demonstrated
that it was possible to reliably detect mutations at 1% allele
frequency (data not shown). Sequence coverage was assessed
considering the number and distribution of reads that were
present in the target DNA regions. Each sample had approx-
imately 317000 mapped reads with a mean read length of
107 bp that generates approximately 23Mb of sequence with
depth of coverage of 1400 reads.
3.2. Detection of Mutations in Inherited PCC/PGL/HNPGL
Genes. 21 patients were known to harbour a germline muta-
tion in an inheritedPCC/PGLgene (VHL= 10,RET =3,NF1=
1, SDHB = 5, SDHC = 1, and SDHD = 1). 13 of these mutations
(RET (𝑛 = 3) and VHL (𝑛 = 10)) were detected by NGS in 13
tumours (see Table 1) and 8 patients had a clinical or previous
molecular diagnosis of a germline inherited PCC/PGL gene
mutation (NF1 (𝑛 = 1), SDHB (𝑛 = 5), SDHC (𝑛 = 1), and
SDHD (𝑛 = 1)) that was not covered by the NGS assay. No
mutations in inherited PCC/PGL genes were detected in the
64 sporadic tumours.
3.3. Detection of Activating Mutations in Protooncogenes
and Tumour Suppressor Genes. Six tumours (PCC = 6/60,
PGL = 0/5, and HNPGL = 0/20) harboured an activating
missense mutation in the HRAS hotspot region of codons
13 and 61 (c.37G>C; p.G13R = 1 and c.182A>G; p.Q61R
= 5), giving an overall frequency of 7.1% (6/85, 95% CI
= 2.63%–14.73%). In each case the somatic status of the
mutations was confirmed when the detected mutation was
absent in matched constitutional DNA (blood) (Table 2). In
one PCC tumour (1/85) an activating BRAF mutation was
identified (c.1799T>A; p.V600E, 1.2%, 95% CI = 0%–6.38%)
(Table 2). In two tumours a missense mutation (c.1010G>A;
p.R337H, 2/85, 2.4%, 95% CI = 0.29%–8.2%) occurring in
the tetramerisation domain of TP53 protein was identified
(Table 2).
3.4. Exclusion of Mutations in Protooncogene Hotspots. No
mutations were detected at hotspot mutation regions in 11
oncogenes frequently mutated in human cancer (AKT, MET,
PIK3CA, KRAS, NRAS, IDH1, IDH2, NOTCH, SMO, ABL,
and EGFR).
3.5. Relationship between Clinical Status and HRAS Muta-
tions. We investigated the relationships between HRAS
mutation and tumour location and presence or absence of an
inherited PCC/PGL/HNPGL gene mutation. The frequency
ofHRASmutations in PCC, PGL, andHNPGLwas 6/60 (10%,
95% CI = 3.76%–20.51%), 0/5 (0%, 95% CI = 0%–52.18%),
and 0/20 (0%, 95% CI = 0%–16.84%), respectively. Among 21
tumours from patients with known inherited disease and/or
detectable mutation in inherited PCC/PGL/HNPGL genes
there were no HRAS mutations (0%, 95% CI = 0%–16.11%)
whereas a mutation was present in 6/64 (9.4%, 95% CI =
3.52%–19.30%) of patients without a clinical diagnosis of
inherited PCC/PGL/HNPGL or a detectable mutation in an
inherited PCC/PGL/HNPGL gene (𝑃 = 0.33).
To further investigate possible relationships between
these attributes we combined our data for HRAS mutation
status with 18 mutations in 353 PCC/PGL/HNPGL from
two previously published studies (Tables 3 and 4) [19, 20].
Meta-analysis results showed that the overall prevalence of
HRASmutations in the cohort of PCC/PGL is 5.48% (24/438,
95% CI = 3.54%–8.04%) increasing to 8.9% (24/269, 95%
CI = 5.80%–12.98%) considering cases without an inherited
PCC/PGL gene mutation and to 9.87% (23/233, 95% CI =
6.36%–14.44%) considering only PCC samples without an
inherited PCC/PGL gene. In PCC/PGL with an inherited
gene mutation theHRASmutation frequency was 0% (0/148,
95% CI = 0%–2.46%) (PCC/PGL unknown mutation versus
PCC/PGL known mutation, 𝑃 = 0.0001).
4. Discussion
A wide repertoire of genetic and epigenetic events can
be implicated in human neoplasia. Previous studies have
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Table 2: Oncogene mutations identified in next generation sequencing analysis of 85 PCC/PGL/HNPGL.
Tumour ID Clinical diagnosis Type of tumour Gene Codon change Aminoacid change Allele frequency
P19 Phaeochromocytoma PCC HRAS c.37G>C G13R 72%
P20 Phaeochromocytoma PCC HRAS c.182A>G Q61R 36%
P21 Phaeochromocytoma PCC HRAS c.182A>G Q61R 27%
P22 Phaeochromocytoma PCC HRAS c.182A>G Q61R 40%
P23 Phaeochromocytoma PCC HRAS c.182A>G Q61R 50%
P24 Phaeochromocytoma PCC HRAS c.182A>G Q61R 26%
P25 Phaeochromocytoma PCC BRAF c.1799T>A V600E 10%
P26 Phaeochromocytoma PCC TP53 c.1010G>A R337H 4%
P27 Phaeochromocytoma PCC TP53 c.1010G>A R337H 21%
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Figure 1: Comparison of somatic variant frequencies in multiple cancer genes in different cancer types.
demonstrated that tumour suppressor gene (TSG) inacti-
vation and oncogene activation in PCC/PGL may result
from somatic copy number abnormalities (SCNA), intragenic
mutations, and epigenetic silencing of transcription by pro-
moter methylation [22]. Common copy number changes in
PCC include loss of chromosomes 1p, 3q, 3p, 11p, 11q, 6q, 17p,
and 22 [23–27] and gain of chromosomes 9q, 17q, 19p13.3, and
20q [28, 29]. Epigenetic inactivation of candidate TSGs has
been reported relatively frequently in PCC/PGL. Thus pro-
moter methylation of candidate TSGs including RASSF1A,
FLIP, TSP1, DCR1, DCR2, DR4, DR5, CASP8, and HIC1 was
reported at a frequency of>20%of tumours analysed [30–32].
Until recently, investigations of patterns of somaticmutations
in PCC/PGL/HNPGL had concentrated on analysing genes
known to be associated with inherited PCC/PGL/HNPGL.
ThusNF1, VHL, RET, andMAX germline and somatic muta-
tions have been reported in 3–25%, 13–9%, 5–5%, and 1–3% of
tumours, respectively [33]. Recently activating mutations in
HIF2A andHRASwere reported in a subset of these tumours
[6, 7, 19, 20]. Whilst HIF2A mutations may be found in
multiple tumours frompatientswithout a detectable germline
mutation (suggesting low level constitutional mosaicism)
or occasionally as a germline mutation [5], to date HRAS
mutations have only been detected as somatic changes
(germline HRAS mutations are associated with Costello
syndrome but PCC/PGL/HNPGL are apparently not a feature
of this disorder) [34]. The frequency of HRAS mutations
in our cohort was similar to that in other recent studies.
HRAS mutation hotspots at codons 13 and 61 affect the RAS
GTP hydrolysis domain, leading to a constitutive activated
state with resistance to upstream inhibitory proteins, such
as neurofibromin (NF1 gene product). This overactive RAS
signalling leads to increased activity of downstream effectors,
most notably the RAS/RAF/ERK and PI3K/AKT/mTOR
signalling pathways linked to increased cell proliferation
and tumour formation [14–18]. The identification of HRAS
mutations as a new pathogenetic driver in sporadic PCC
opens up the possibility of new therapeutic approaches—
though in most cases surgical removal seems likely to be
the treatment of choice. BRAF mutations are found in
multiple cancer types (Figure 1), notably those that are also
associated with mutations in isoforms of RAS (i.e., malignant
melanoma, colorectal cancer). Our results demonstrate for
the first time a somaticBRAFmutation in PCC/PGL/HNPGL
samples. The mutation detected is the most common BRAF
mutation found in human neoplasia and results from a T
to A transversion at nucleotide 1799. c.1799T>A (p.V600E)
mutant BRAF proteins are characterized by an increased
kinase activity and have been demonstrated to induce cellular
transformation in in vitro studies [35].
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Table 4:𝐻𝑅𝐴𝑆mutations frequencies in phaeochromocytoma and paraganglioma.
Study Overall frequency of𝐻𝑅𝐴𝑆mutations
Frequency of𝐻𝑅𝐴𝑆 in
PCC/PGL with unknown mutations
Frequency of𝐻𝑅𝐴𝑆 in PCC
with unknown mutations
All Positive samples All Positive samples All Positive samples
Current study 7,06% 85 6 12,24% 49 6 13,95% 43 6
Crona et al. [19] 4,88% 82 4 7,14% 56 4 6,00% 50 3
Oudijk et al. [20] 5,17% 271 14 8,54% 164 14 10,00% 140 14
Total 5,48% 438 24 8,92% 269 24 9,87% 233 23
Since BRAF is involved in ERK kinase activation in the
RAS/RAF/ERK signalling pathway, it will be interesting to
further compare the biological behaviour ofHRAS and BRAF
mutated tumours in order to determine whether they have
similar clinical characteristics and to determine if they will
fall into the “cluster 2” group of gene expression patterns.
PCC/PGLs with BRAF V600Emutationsmay be predicted to
respond to BRAF and MEK inhibitors, such as vemurafenib
and trametinib/selumetinib, better than wild type BRAF
tumours [36–39].
The presence of BRAF andHRASmutations in PCC/PGL
suggests that activation of the RAS/RAF/ERK signalling
pathway can be triggered by mutations at various levels in
the pathway. An implementation of the panel used, including
more genes of this pathway, could be useful to identify low
frequency somatic variants in PCC/PGL. Loss of heterozy-
gosity at 17p13 is frequent in many tumour types including
breast [40], colon [41], and hepatocellular cancers [42] and
phaeochromocytoma [22], with an occurrence ranging from
30% to 60%. The tumour suppressor gene TP53maps in this
region and has been demonstrated to be implicated in the
tumourigenesis process in different types of cancers. Loss of
TP53 function could arise from epigenetic alterations allelic
losses and mutational events. Due to its involvement in car-
cinogenesis, TP53 has been intensively studied in PCC/PGL
but, despite frequent allele loss, TP53 mutations have been
reported rarely [23, 43–45]. However, in our series, NGS
results followed by direct DNA sequencing demonstrated the
presence in two sporadic PCC samples of a somatic TP53
gene mutation (c.1010G>A; p.R337H) (Table 2). The R337H
substitution has previously been extensively characterised
as a founder germline mutation and the altered protein
demonstrated to act as a conditional mutant that loses its
function only when a small increase in intracellular pH
occurs in cells. Initially, the c.1010G>A (R337H) mutation
was thought to predispose only to adrenal cortical carcinoma
(ACC) (for which the penetrance of the allele has been
estimated to be ∼10% and the increased risk was estimated at
a 20,000-fold increase [46, 47]); however, several studies have
highlighted it in association with Li Fraumeni-like syndrome
[48], breast cancer [49, 50], choroid plexus carcinoma, and
osteosarcoma [51, 52]. To our knowledge, this is the first
report on this mutation in sporadic phaeochromocytoma. By
using an approach utilising targeted deep sequencingwewere
able to confidently detect the presence or absence of a large
repertoire of hotspot mutations, paying particular attention
to a set of them.The absence of mutations in ALK and NRAS
was of particular interest (Figure 1) because mutations in
these genes have been described in neuroblastoma (∼9.2%,
0.83% of cases, resp.; Figure 1) and some epigenetically inacti-
vated candidate TSGs (i.e.,RASSF1A, FLIP, CASP8, andHIC1)
are common to both PCC/PGL andneuroblastoma. IDH1 and
IDH2 mutations have been described in gliomas, leukaemia,
and othermalignancies (Figure 1) andmay causemethylation
abnormalities by a similar mechanism to that associated
with SDH gene subunit mutations [53]. Therefore despite
IDH1/IDH2 hotspot regions potentially representing candi-
date genes for somatic inactivation in PCC/PGL/HNPGL,
no mutations were identified (Figure 1) [54]. Our findings
are consistent with the hypothesis that mutations in HRAS
and inherited PCC/PGL genes are mutually exclusive driver
mutations (though comprehensive analysis of all inherited
phaeochromocytoma/PGL genes has not been undertaken
in all patients). If this hypothesis is correct, it can be
suggested thatHRAS profiling of PCC/PGL/HNPGL tumour
material could aid the management of patients by enabling
enhanced stratification of their risk of inherited disease.
Furthermore, we suggest that molecular profiling should be
expanded to include BRAF analysis. Currently histopathol-
ogy cannot reliably predict the likelihood of malignancy in
PCC/PGL/HNPGLwhereas the presence of a germline SDHB
mutation is associated with an increased risk of malignancy
[55–57]. The identification, careful characterisation, and
follow-up of cohorts of patients with HRAS/BRAF mutation
positive tumours could enable the natural history of such
tumours (e.g., absence of malignant or recurrent disease) and
so facilitate personalised management of patients with these
tumours.
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